E
36.46
0.53 (1.48%)
| Previous Close | 35.93 |
| Open | 36.28 |
| Volume | 1,682,597 |
| Avg. Volume (3M) | 2,111,236 |
| Market Cap | 10,412,210,176 |
| Price / Earnings (TTM) | 23.52 |
| Price / Earnings (Forward) | 21.51 |
| Price / Sales | 4.81 |
| Price / Book | 4.18 |
| 52 Weeks Range | |
| Earnings Date | 4 Feb 2025 - 10 Feb 2025 |
| Profit Margin | 22.43% |
| Operating Margin (TTM) | 34.81% |
| Diluted EPS (TTM) | 1.55 |
| Quarterly Revenue Growth (YOY) | 14.30% |
| Quarterly Earnings Growth (YOY) | 11,232.70% |
| Total Debt/Equity (MRQ) | 8.55% |
| Current Ratio (MRQ) | 3.93 |
| Operating Cash Flow (TTM) | 470.28 M |
| Levered Free Cash Flow (TTM) | 431.27 M |
| Return on Assets (TTM) | 12.81% |
| Return on Equity (TTM) | 20.20% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Exelixis, Inc. | Bullish | Bullish |
AIStockmoo Score
-1.9
| Analyst Consensus | -1.5 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -1.88 |
|
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.59% |
| % Held by Institutions | 89.26% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 40.00 (BMO Capital, 9.71%) | Hold |
| Median | 34.00 (-6.75%) | |
| Low | 28.00 (Morgan Stanley, -23.20%) | Hold |
| Average | 34.25 (-6.06%) | |
| Total | 7 Buy, 5 Hold | |
| Avg. Price @ Call | 31.35 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BMO Capital | 20 Dec 2024 | 40.00 (9.71%) | Hold | 33.29 |
| 30 Oct 2024 | 36.00 (-1.26%) | Buy | 32.44 | |
| B of A Securities | 17 Dec 2024 | 39.00 (6.97%) | Hold | 34.69 |
| 15 Oct 2024 | 32.00 (-12.23%) | Buy | 28.50 | |
| Guggenheim | 30 Oct 2024 | 33.00 (-9.49%) | Buy | 32.44 |
| Piper Sandler | 30 Oct 2024 | 36.00 (-1.26%) | Buy | 32.44 |
| RBC Capital | 30 Oct 2024 | 34.00 (-6.75%) | Buy | 32.44 |
| 16 Oct 2024 | 34.00 (-6.75%) | Buy | 29.35 | |
| Stephens & Co. | 30 Oct 2024 | 29.00 (-20.46%) | Hold | 32.44 |
| Truist Securities | 30 Oct 2024 | 38.00 (4.22%) | Buy | 32.44 |
| Wells Fargo | 30 Oct 2024 | 36.00 (-1.26%) | Buy | 32.44 |
| TD Cowen | 21 Oct 2024 | 34.00 (-6.75%) | Buy | 28.66 |
| JMP Securities | 16 Oct 2024 | 34.00 (-6.75%) | Buy | 29.35 |
| 11 Oct 2024 | 29.00 (-20.46%) | Buy | 26.23 | |
| Stifel | 16 Oct 2024 | 30.00 (-17.72%) | Hold | 29.35 |
| Morgan Stanley | 11 Oct 2024 | 28.00 (-23.20%) | Hold | 26.23 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |